Medabon: new product for early termination of pregnancy.
Article Type: Brief article
Subject: Pregnant women (Care and treatment)
Abortion, Therapeutic (Methods)
Pub Date: 11/01/2008
Publication: Name: Reproductive Health Matters Publisher: Reproductive Health Matters Audience: General Format: Magazine/Journal Subject: Family and marriage; Health; Women's issues/gender studies Copyright: COPYRIGHT 2008 Reproductive Health Matters ISSN: 0968-8080
Issue: Date: Nov, 2008 Source Volume: 16 Source Issue: 32
Topic: Event Code: 331 Product development; 336 Product introduction Advertising Code: 57 New Products/Services
Product: Name: Medabon (Medication); Medabon (Medication)
Accession Number: 192393430
Full Text: Medabon is the first dedicated product for use in early medical abortion. The Concept Foundation has worked for several years on the development of the product and is preparing now for its introduction into health systems to make it a viable choice for women worldwide. Medabon comprises mifepristone (taken orally) and misoprostol (taken vaginally) in a combination pack and is based on the recommended regimen by WHO and the Royal College of Obstetricians and Gynaecologists for use up to 63 days of pregnancy. The first regulatory approval for Medabon has been obtained in Nepal. Other first-wave countries are Cambodia, Ethiopia, Ghana, India, Mongolia, South Africa, Tunisia, Turkey and Viet Nam.

The first Medabon Bulletin has been disseminated with important information about the product and its planned availability. (1)

(1.) Concept Foundation. Medabon Bulletin, 31 January 2008, Volume 1, Issue 1. At:
Gale Copyright: Copyright 2008 Gale, Cengage Learning. All rights reserved.